


PHARMACEUTICAL 2017

Nexvet Biopharma plc Rank 141 of 313





PHARMACEUTICAL 2017

Nexvet Biopharma plc Rank 141 of 313

The relative strengths and weaknesses of Nexvet Biopharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nexvet Biopharma plc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 123% points. The greatest weakness of Nexvet Biopharma plc is the variable Research and Development, reducing the Economic Capital Ratio by 92% points.

The company's Economic Capital Ratio, given in the ranking table, is -147%, being 269% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	34,962
Cost of Goods Sold	0
Intangible Assets	74
Liabilities, Current	5,047
Liabilities, Non-Current	141
Other Assets	380
Other Compr. Net Income	-852
Other Expenses	0
Other Liabilities	0
Other Net Income	335
Property and Equipment	4,908
Research and Development	14,877
Revenues	4,490
Selling, General and Administrative Expense	7,293

Output Variable	Value in 1000 USD
Assets	40,324
Liabilities	5,188
Expenses	22,170
Stockholders Equity	35,136
Net Income	-17,345
Comprehensive Net Income	-17,771
Economic Capital Ratio	-147%